Fulgent Genetics, Inc. - Common Stock (FLGT)

Fulgent Genetics (FLGT) Earnings Transcript

Fulgent Genetics (FLGT) Earnings Call Transcript

Fulgent Genetics Q3 2025 earnings beat expectations with a surprise profit, causing a 4% pre-market stock surge. The company also raised its full-year guidance.

Fulgent Genetics has seen its fortunes shift since the pandemic. Is it a solid investment or a risky bet? Join us as we break down its performance and management decisions.

The next-generation diagnostics specialist had a beat-and-raise second quarter.

As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Fulgent Genetics exceeded expectations in the fourth quarter of 2024, showcasing robust revenue growth and a GAAP loss.

FLGT stock results show that Fulgent Genetics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

Digital health stocks are becoming increasingly relevant as more and more people seek greater control over their health.

Companies Reporting Before The Bell • Arcutis Biotherapeutics (NASDAQ:ARQT) is expected to report quarterly loss at $0.86 per share on revenue of $32.83 million.